Phase 2 study of T138067-sodium in patients with malignant glioma
We studied the activity of T138067-sodium in patients with malignant gliomas. T138067-sodium is a un
ASCO - A phase II study of T138067-sodium in prior taxane-treated
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.
Sheet2
8, "A Phase I/II open Label Study of T138067- sodium Patients With Advanced Surgically Unresectable Hepatocellalur Carcinoma"
Clinical Trial: T138067 Sodium in Treating Patients With Advanced
PURPOSE: Phase I trial to study the effectiveness of T138067 sodium in treating Official Title: Phase I Study of T138067 Sodium in Patients With
UCSF - UCSF Comprehensive Cancer Center - People - Thierry Marie
A Phase II Study of T138067-Sodium in Prior Taxane-Treated Patients (Pts) with Locally Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).

Clinical Trial: T138067 Sodium in Treating Patients With Advanced
PURPOSE: Phase I trial to study the effectiveness of T138067 sodium in treating Official Title: Phase I Study of T138067 Sodium in Patients With
Clinical Trial: T138067 Versus Doxorubicin in Chemotherapy-Naive
A total of 750 subjects will be enrolled in this study. Drug: T138067 intravenous Drug: doxorubicin intravenous, Phase II · Phase III
UCSF - UCSF Comprehensive Cancer Center - People - Thierry Marie
A Phase II Study of T138067-Sodium in Prior Taxane-Treated Patients (Pts) with Locally Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful
A phase II study of T138067-sodium in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002;20:572a.
DOI: 10.1634/theoncologist.11-7-790 2006;11;790-800 Oncologist
A phase II study of T138067-sodium. in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc. AmSoc ClinOncol 2002;20:572a.
Recombinant leukocyte interferon, doxorubicin, and 5FUDR in
AP (2002) A phase II study of T138067- sodium in patients. (pts) with unresectable hepatocellular carcinoma. Proc Am Soc. Clin Onc 21:144a
Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride
the investigational antimicrotubule agent T138067 before treatment with tasidotin Phase I study with a weekly 1 h infusion of paclitaxel in heavily
CURRICULUM VITAE
Donehower R.C., Schwartz G., Wolff A.C., Olivo N., Burks K.L., Wright M., Walling J., Rowinsky, E.K A phase I pharmacokinetic study of T138067